Latest & greatest articles for clopidogrel

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on clopidogrel or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on clopidogrel and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for clopidogrel

121. Clopidogrel compared with other antiplatelet agents for secondary prevention of vascular events in adults undergoing percutaneous coronary intervention: clinical and cost-effectiveness analyses

Clopidogrel compared with other antiplatelet agents for secondary prevention of vascular events in adults undergoing percutaneous coronary intervention: clinical and cost-effectiveness analyses Clopidogrel compared with other antiplatelet agents for secondary prevention of vascular events in adults undergoing percutaneous coronary intervention: clinical and cost-effectiveness analyses Clopidogrel compared with other antiplatelet agents for secondary prevention of vascular events in adults (...) M. Clopidogrel compared with other antiplatelet agents for secondary prevention of vascular events in adults undergoing percutaneous coronary intervention: clinical and cost-effectiveness analyses. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Technology report no 131. 2010 Authors' conclusions The estimates of relative effectiveness for clopidogrel and ticlopidine with ASA suggest that the optimal therapeutic choice is unclear. Clopidogrel and ticlopidine are at least

2010 Health Technology Assessment (HTA) Database.

122. Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults with acute coronary syndrome or peripheral vascular disease: clinical and cost-effectiveness analyses

Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults with acute coronary syndrome or peripheral vascular disease: clinical and cost-effectiveness analyses Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults with acute coronary syndrome or peripheral vascular disease: clinical and cost-effectiveness analyses Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events (...) . Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults with acute coronary syndrome or peripheral vascular disease: clinical and cost-effectiveness analyses. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Technology report no. 133. 2010 Authors' conclusions In patients with ACS without ST-segment elevation, therapy with clopidogrel and ASA was more efficacious than ASA alone, with an increased risk of major bleeding. A post hoc analysis

2010 Health Technology Assessment (HTA) Database.

123. Clopidogrel with or without omeprazole in coronary artery disease. Full Text available with Trip Pro

Clopidogrel with or without omeprazole in coronary artery disease. Gastrointestinal complications are an important problem of antithrombotic therapy. Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy. Recently, concerns have been raised about the potential for PPIs to blunt the efficacy of clopidogrel.We randomly assigned patients with an indication for dual (...) antiplatelet therapy to receive clopidogrel in combination with either omeprazole or placebo, in addition to aspirin. The primary gastrointestinal end point was a composite of overt or occult bleeding, symptomatic gastroduodenal ulcers or erosions, obstruction, or perforation. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, revascularization, or stroke. The trial was terminated prematurely when the sponsor lost financing.We planned

2010 NEJM Controlled trial quality: predicted high

124. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. (Abstract)

Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Clopidogrel and aspirin are the most commonly used antiplatelet therapies for percutaneous coronary intervention (PCI). We assessed the effect of various clopidogrel and aspirin regimens in prevention of major cardiovascular events and stent thrombosis in patients undergoing (...) PCI.The CURRENT-OASIS 7 trial was undertaken in 597 centres in 39 countries. 25,086 individuals with acute coronary syndromes and intended early PCI were randomly assigned to double-dose (600 mg on day 1, 150 mg on days 2-7, then 75 mg daily) versus standard-dose (300 mg on day 1 then 75 mg daily) clopidogrel, and high-dose (300-325 mg daily) versus low-dose (75-100 mg daily) aspirin. Randomisation was done with a 24 h computerised central automated voice response system. The clopidogrel dose

2010 Lancet Controlled trial quality: predicted high

125. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. Full Text available with Trip Pro

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. Clopidogrel and aspirin are widely used for patients with acute coronary syndromes and those undergoing percutaneous coronary intervention (PCI). However, evidence-based guidelines for dosing have not been established for either agent.We randomly assigned, in a 2-by-2 factorial design, 25,086 patients with an acute coronary syndrome who were referred for an invasive strategy to either double-dose clopidogrel (a 600-mg (...) loading dose on day 1, followed by 150 mg daily for 6 days and 75 mg daily thereafter) or standard-dose clopidogrel (a 300-mg loading dose and 75 mg daily thereafter) and either higher-dose aspirin (300 to 325 mg daily) or lower-dose aspirin (75 to 100 mg daily). The primary outcome was cardiovascular death, myocardial infarction, or stroke at 30 days.The primary outcome occurred in 4.2% of patients assigned to double-dose clopidogrel as compared with 4.4% assigned to standard-dose clopidogrel (hazard

2010 NEJM Controlled trial quality: predicted high

126. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. Full Text available with Trip Pro

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. It has been suggested that clopidogrel may be less effective in reducing the rate of cardiovascular events among persons who are carriers of loss-of-function CYP2C19 alleles that are associated with reduced conversion of clopidogrel to its active metabolite.We genotyped patients from two large, randomized trials that showed that clopidogrel, as compared with placebo, reduced the rate of cardiovascular events (the primary efficacy (...) outcome) among patients with acute coronary syndromes and among patients with atrial fibrillation. Patients were genotyped for three single-nucleotide polymorphisms (*2, *3, *17) that define the major CYP2C19 alleles.Among 5059 genotyped patients with acute coronary syndromes, clopidogrel as compared with placebo significantly reduced the rate of the primary efficacy outcome, irrespective of the genetically determined metabolizer phenotype (P=0.12 for heterogeneity). The effect of clopidogrel

2010 NEJM Controlled trial quality: predicted high

127. A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UK

A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UK A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UK A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UK Karnon J, Holmes MW, Williams R, Bakhai A, Brennan A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study aimed to assess the incremental cost-effectiveness of treatment for one month or for one year, with clopidogrel in addition to standard therapy, for patients diagnosed with ST-segment elevation myocardial infarction, in the UK. The authors concluded that the addition of clopidogrel to standard therapy was cost

2010 NHS Economic Evaluation Database.

128. CYP2C19 genotyping to predict response to clopidogrel

CYP2C19 genotyping to predict response to clopidogrel CYP2C19 genotyping to predict response to clopidogrel CYP2C19 genotyping to predict response to clopidogrel Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation CYP2C19 genotyping to predict response to clopidogrel. Lansdale: HAYES, Inc.. Genetic Testing Publication. 2010 Authors' objectives Dual antiplatelet (...) therapy with aspirin and a thienopyridine is recommended both in patients after acute myocardial infarction (MI) and in patients undergoing percutaneous coronary intervention (PCI) procedures with stenting. Every year in the United States, there are approximately 1.3 million inpatient PCIs and 0.9 million patients who experience an MI. Clopidogrel (trade name Plavix®; Sanofi-Aventis Inc.) is the main thienopyridine prescribed for antiplatelet therapy; in 2009, the Food and Drug Administration (FDA

2010 Health Technology Assessment (HTA) Database.

129. New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis

New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

130. Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial Full Text available with Trip Pro

Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial Thurston SJ, Heeg B, de Charro F, van Hout B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of combined treatment with clopidogrel and aspirin compared with aspirin alone, for patients with ST-segment elevation myocardial infarction. The authors concluded that clopidogrel, combined with aspirin and given according to the Clopidogrel as Adjunctive Reperfusion

2010 NHS Economic Evaluation Database.

131. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty Full Text available with Trip Pro

Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty Our aim was to determine whether a 600-mg loading dose of clopidogrel compared with 300 mg results in improved clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).A 600-mg loading dose of clopidogrel compared with 300 mg provides more rapid and potent inhibition of platelet (...) activation.In the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial, 3,602 patients with STEMI undergoing primary PCI were randomized to bivalirudin (n = 1,800) or unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor (n = 1,802). Randomization was stratified by thienopyridine loading dose, which was determined before random assignment.Patients in the 600-mg (n = 2,158) compared with the 300-mg (n = 1,153) clopidogrel loading dose group had

2009 EvidenceUpdates Controlled trial quality: predicted high

132. Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention Full Text available with Trip Pro

Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention Inhibition of platelet aggregation after aspirin or clopidogrel intake varies greatly among patients, and previous studies have suggested that poor response to oral antiplatelet agents may increase the risk of thrombotic events, especially after coronary angioplasty. Whether this reflects suboptimal platelet inhibition per se, which might benefit (...) from more potent antiplatelet agents such as tirofiban, is unknown.We screened 1277 patients to enroll 93 aspirin, 147 clopidogrel, and 23 dual poor responders, based on a point-of-care assay, who underwent elective coronary angioplasty at 10 European sites for stable or low-risk unstable coronary artery disease. Patients were randomly assigned in a double-blind manner to receive either tirofiban (n=132) or placebo (n=131) on top of standard aspirin and clopidogrel therapy. The primary end point

2009 EvidenceUpdates Controlled trial quality: predicted high

133. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardi Full Text available with Trip Pro

Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardi Prasugrel is a novel thienopyridine that reduces new or recurrent myocardial infarctions (MIs) compared with clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. This effect must be balanced (...) against an increased bleeding risk. We aimed to characterize the effect of prasugrel with respect to the type, size, and timing of MI using the universal classification of MI.We studied 13 608 patients with acute coronary syndrome undergoing percutaneous coronary intervention randomized to prasugrel or clopidogrel and treated for 6 to 15 months in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI

2009 EvidenceUpdates Controlled trial quality: uncertain

134. Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial Full Text available with Trip Pro

Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial Chronic heart failure remains a major cause of mortality and morbidity. The role of antithrombotic therapy in patients with chronic heart failure has long been debated. The objective of this study was to determine the optimal antithrombotic agent for heart failure patients with reduced ejection fractions who are in sinus (...) rhythm.This prospective, randomized clinical trial of open-label warfarin (target international normalized ratio of 2.5 to 3.0) and double-blind treatment with either aspirin (162 mg once daily) or clopidogrel (75 mg once daily) had a 30-month enrollment period and a minimum of 12 months of treatment. We enrolled 1587 men and women >/=18 years of age with symptomatic heart failure for at least 3 months who were in sinus rhythm and had left ventricular ejection fraction of

2009 EvidenceUpdates Controlled trial quality: predicted high

135. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel Full Text available with Trip Pro

A population-based study of the drug interaction between proton pump inhibitors and clopidogrel Most proton pump inhibitors inhibit the bioactivation of clopidogrel to its active metabolite. The clinical significance of this drug interaction is unknown.We conducted a population-based nested case-control study among patients aged 66 years or older who commenced clopidogrel between Apr. 1, 2002, and Dec. 31, 2007, following hospital discharge after treatment of acute myocardial infarction (...) . The cases in our study were those readmitted with acute myocardial infarction within 90 days after discharge. We performed a secondary analysis considering events within 1 year. Event-free controls (at a ratio of 3:1) were matched to cases on age, percutaneous coronary intervention and a validated risk score. We categorized exposure to proton pump inhibitors before the index date as current (within 30 days), previous (31-90 days) or remote (91-180 days).Among 13 636 patients prescribed clopidogrel

2009 EvidenceUpdates

136. Bivalirudin and Clopidogrel With and Without Eptifibatide for Elective Stenting: Effects on Platelet Function, Thrombelastographic Indexes, and Their Relation to Periprocedural Infarction Full Text available with Trip Pro

Bivalirudin and Clopidogrel With and Without Eptifibatide for Elective Stenting: Effects on Platelet Function, Thrombelastographic Indexes, and Their Relation to Periprocedural Infarction The primary objective of this study was to compare the effect of therapy with bivalirudin alone versus bivalirudin plus eptifibatide on platelet reactivity measured by turbidometric aggregometry and thrombin-induced platelet-fibrin clot strength (TIP-FCS) measured by thrombelastography in percutaneous coronary (...) intervention (PCI) patients. The secondary aim was to study the relation of platelet aggregation and TIP-FCS to the occurrence of periprocedural infarction.Bivalirudin is commonly administered alone to clopidogrel naïve (CN) patients and to patients on maintenance clopidogrel therapy (MT) undergoing elective stenting. The effect of adding eptifibatide to bivalirudin on platelet reactivity (PR) and TIP-FCS, and their relation to periprocedural infarction in these patients are unknown.Patients (n = 200

2009 EvidenceUpdates Controlled trial quality: uncertain

137. Clopidogrel BGR (previously Zylagren) - clopidogrel

Clopidogrel BGR (previously Zylagren) - clopidogrel European Medicines Agency Evaluation of Medicines for Human Use 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 85 45 E-mail: mail@emea.europa.eu http://www.emea.europa.eu © European Medicines Agency, 2009. Reproduction is authorised provided the source is acknowledged. Doc. Ref.:EMEA/507032/2009 CHMP ASSESSMENT REPORT FOR ZYLAGREN International Nonproprietary Name: clopidogrel Procedure (...) of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a Marketing Authorisation to Zylagren on 25 June 2009. The applicant provided the letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 23 June 2009. 4/13 © EMEA 2009 2. SCIENTIFIC DISCUSSION .1 Introduction ylagren 75mg film-coated tablets are generic medicinal products containing clopidogrel as lopidogrel is a non-competitive inhibitor of adenosine

2009 European Medicines Agency - EPARs

138. Clopidogrel ratiopharm GmbH

Clopidogrel ratiopharm GmbH European Medicines Agency Evaluation of Medicines for Human Use 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 85 45 E-mail: mail@emea.europa.eu http://www.emea.europa.eu © European Medicines Agency, 2009. Reproduction is authorised provided the source is acknowledged. Doc. Ref:EMEA/533408/2009 ASSESSMENT REPORT FOR Clopidogrel ratiopharm GmbH International Nonproprietary Name: clopidogrel Procedure No. EMEA/H/C/1165 (...) INFORMATION ON THE PROCEDURE 1.1 Submission of the dossier The applicant Acino Pharma GmbH submitted on 17 April 2009 an application for Marketing Authorisation to the European Medicines Agency (EMEA) for Clopidogrel ratiopharm GmbH, in accordance with the centralised procedure falling within the scope of the Annex to Regulation (EC) 726/2004 under Article 3 (3) – ‘Generic of a Centrally authorised product’. The legal basis for this application refers to Article 10(1). The chosen reference product

2009 European Medicines Agency - EPARs

139. Clopidogrel Acino

Clopidogrel Acino European Medicines Agency Evaluation of Medicines for Human Use 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 85 45 E-mail: mail@emea.europa.eu http://www.emea.europa.eu © European Medicines Agency, 2009. Reproduction is authorised provided the source is acknowledged. Doc. Ref:EMEA/533424/2009 ASSESSMENT REPORT FOR Clopidogrel Acino International Nonproprietary Name: clopidogrel Procedure No. EMEA/H/C/1166 Assessment Report (...) product no longer authorised3/13 1. BACKGROUND INFORMATION ON THE PROCEDURE 1.1 Submission of the dossier The applicant Acino Pharma GmbH submitted on 17 April 2009 an application for Marketing Authorisation to the European Medicines Agency (EMEA) for Clopidogrel Acino, in accordance with the centralised procedure falling within the scope of the Annex to Regulation (EC) 726/2004 under Article 3 (3) – ‘Generic of a Centrally authorised product’. The legal basis for this application refers to Article 10

2009 European Medicines Agency - EPARs

140. Clopidogrel TAD

Clopidogrel TAD European Medicines Agency 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 85 45 E-mail: mail@emea.europa.eu http://www.emea.europa.eu © European Medicines Agency, 2009. Reproduction is authorised provided the source is acknowledged. Doc. Ref.:EMEA/506902/2009 CHMP ASSESSMENT REPORT FOR Clopidogrel TAD International Nonproprietary Name: clopidogrel Procedure No. EMEA/H/C/001136 Assessment Report as adopted by the CHMP with all (...) of the dossier Tad Pharma GmbH submitted on 20 February 2009 an application for Marketing Authorisation to the European Medicines Agency (EMEA) for Clopidogrel Tad , in accordance with the centralised procedure falling within the scope of the Annex to Regulation (EC) 726/2004 under Article 3 (3) – ‘Generic of a Centrally authorised product’. The legal basis for this application refers to Article 10(1) of Directive 2001/83/EC. The chosen reference product is: ¦ Medicinal product which is or has been

2009 European Medicines Agency - EPARs